Hinge Health vs Benchling: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Hinge Health and Benchling.
Hinge Health
Digital musculoskeletal (MSK) therapy platform delivering personalised exercise therapy for back, neck, hip, and knee pain through wearable sensors and coaching.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Benchling
Life science R&D platform combining electronic lab notebook, molecular biology tools, and LIMS (lab information management) for biopharma, biotech, and agricultural science.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Key differences for employees
Equity structure
Hinge Health grants ISO/NSO with strike prices ranging from $20–$32 depending on your grant year. Benchling grants ISO/NSO with strike prices from $18–$30.
Secondary market premium
The secondary market is pricing Hinge Health at a +3% premium over its last primary round ($6.2B → $6.4B). Benchling trades at +3% over its last round ($6.1B → $6.3B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Hinge Health runs at $0.3B ARR, growing +30% YoY (solid). Benchling runs at $0.1B ARR, growing +30% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Hinge Health: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Benchling: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.